AMG National Trust Bank Sells 834 Shares of Johnson & Johnson (NYSE:JNJ)

AMG National Trust Bank cut its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,856 shares of the company’s stock after selling 834 shares during the quarter. AMG National Trust Bank’s holdings in Johnson & Johnson were worth $11,030,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. RE Dickinson Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the period. Advanced Research Investment Solutions LLC raised its position in shares of Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after buying an additional 120 shares during the last quarter. Morton Brown Family Wealth LLC raised its position in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after buying an additional 78 shares during the last quarter. Professional Financial Advisors LLC raised its position in shares of Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after buying an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $39,000. 68.59% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $169.25 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The firm has a market capitalization of $442.50 billion, a P/E ratio of 23.57, a P/E/G ratio of 3.42 and a beta of 0.57. The business’s 50-day moving average is $166.88 and its two-hundred day moving average is $171.59. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the company earned $2.60 EPS. Analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.67%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson declared that its Board of Directors has initiated a share repurchase plan on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. Sanford C. Bernstein cut their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Barclays started coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. Bank of America decreased their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Morgan Stanley decreased their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a report on Wednesday, October 19th. Finally, Citigroup reduced their target price on shares of Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $184.25.

Insiders Place Their Bets

In other news, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now owns 80,236 shares in the company, valued at $13,764,485.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at $12,366,753.62. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 118,795 shares of company stock worth $20,230,174. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.